# A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer

> **NCT01824524** · PHASE1 · COMPLETED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Hydromorphone

## Key facts

- **NCT ID:** NCT01824524
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01824524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01824524, "A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01824524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*